Large-vessel vasculitis

[1]  P. Jégo,et al.  Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: Multicenter retrospective study of 209 patients. , 2021, Rheumatology.

[2]  G. Guyatt,et al.  2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis , 2021, Arthritis & rheumatology.

[3]  G. Guyatt,et al.  2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis , 2021, Arthritis care & research.

[4]  D. Klatzmann,et al.  Mast cells drive pathologic vascular lesions in Takayasu arteritis. , 2021, The Journal of allergy and clinical immunology.

[5]  D. Misra,et al.  Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis—a systematic review and meta-analysis , 2021, Clinical Rheumatology.

[6]  F. Tubach,et al.  Efficacy and safety of steroid-sparing treatments in giant cell arteritis according to the glucocorticoids tapering regimen: A systematic review and meta-analysis. , 2021, European journal of internal medicine.

[7]  M. Uder,et al.  Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study. , 2021, Rheumatology.

[8]  J. Stone,et al.  Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial , 2021 .

[9]  J. Viallard,et al.  Real-world Risk of Relapse of Giant Cell Arteritis Treated With Tocilizumab: A Retrospective Analysis of 43 Patients , 2021, The Journal of Rheumatology.

[10]  E. Tombetti,et al.  Blood Biomarkers for Monitoring and Prognosis of Large Vessel Vasculitides , 2021, Current Rheumatology Reports.

[11]  J. Pouchot,et al.  Specific Follicular Helper T Cell Signature in Takayasu Arteritis , 2021, Arthritis & rheumatology.

[12]  J. Stone,et al.  Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations , 2021, Arthritis Research & Therapy.

[13]  C. Creuzot-Garcher,et al.  Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis , 2021, Clinical & translational immunology.

[14]  C. Wallace,et al.  Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. , 2020, American journal of human genetics.

[15]  A. Morgan,et al.  Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study , 2020, PLoS medicine.

[16]  J. Pope,et al.  A meta-analysis of the epidemiology of giant cell arteritis across time and space , 2020, Arthritis Research & Therapy.

[17]  P. Merkel,et al.  Clinical course of 602 patients with Takayasu's arteritis: comparison between Childhood-onset versus adult onset disease. , 2020, Rheumatology.

[18]  A. Tomelleri,et al.  Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool. , 2020, RMD open.

[19]  P. Merkel,et al.  Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis , 2020, Arthritis care & research.

[20]  E. Matteson,et al.  Morbidity and Mortality of Large-Vessel Vasculitides , 2020, Current Rheumatology Reports.

[21]  N. Basu,et al.  Evaluation of adjunctive mycophenolate for large vessel giant cell arteritis , 2020, Rheumatology advances in practice.

[22]  M. Dougados,et al.  EULAR definition of difficult-to-treat rheumatoid arthritis , 2020, Annals of the Rheumatic Diseases.

[23]  R. Goel,et al.  Cardiovascular and Renal Morbidity in Takayasu Arteritis: A Population‐Based Retrospective Cohort Study From the United Kingdom , 2020, Arthritis & rheumatology.

[24]  I. Udalova,et al.  ROS-producing immature neutrophils in giant cell arteritis are linked to vascular pathologies , 2020, JCI insight.

[25]  G. Berry,et al.  NOTCH-induced rerouting of endosomal trafficking disables regulatory T-cells in vasculitis. , 2020, The Journal of clinical investigation.

[26]  G. Berry,et al.  Pathogenesis of Giant Cell Arteritis and Takayasu Arteritis—Similarities and Differences , 2020, Current Rheumatology Reports.

[27]  D. Blockmans,et al.  A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis , 2020, Rheumatology and Therapy.

[28]  J. Rudd,et al.  Novel Positron Emission Tomography Tracers for Imaging Vascular Inflammation , 2020, Current Cardiology Reports.

[29]  C. Turesson,et al.  Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: A systematic literature review. , 2020, Seminars in arthritis and rheumatism.

[30]  M. Tomšič,et al.  Identification of microRNAs and their target gene networks implicated in arterial wall remodelling in giant cell arteritis. , 2020, Rheumatology.

[31]  Frederick M. Lang,et al.  GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches , 2020, Nature Reviews Immunology.

[32]  I. Durieu,et al.  Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta‐Analysis , 2020, Arthritis care & research.

[33]  T. Fryer,et al.  Novel Approach to Imaging Active Takayasu Arteritis Using Somatostatin Receptor Positron Emission Tomography/Magnetic Resonance Imaging. , 2020, Circulation. Cardiovascular imaging.

[34]  M. González-Gay,et al.  Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice. , 2020, Clinical and experimental rheumatology.

[35]  P. Merkel,et al.  Patterns of clinical presentation in Takayasu's arteritis. , 2020, Seminars in arthritis and rheumatism.

[36]  N. Basu,et al.  Improving quality of life in vasculitis patients. , 2020, Rheumatology.

[37]  J. Stone,et al.  Ustekinumab for the Treatment of Giant Cell Arteritis , 2020, Arthritis care & research.

[38]  T. Horita,et al.  Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis , 2020, Annals of the Rheumatic Diseases.

[39]  D. Klatzmann,et al.  Targeting JAK/STAT pathway in Takayasu’s arteritis , 2020, Annals of the Rheumatic Diseases.

[40]  Zachary T. Rosenkrans,et al.  ImmunoPET: Concept, Design, and Applications. , 2020, Chemical reviews.

[41]  J. Tarkin,et al.  The Impact of Integrated Noninvasive Imaging in the Management of Takayasu Arteritis. , 2020, JACC. Cardiovascular imaging.

[42]  A. Masamune,et al.  Identification of two major autoantigens negatively regulating endothelial activation in Takayasu arteritis , 2020, Nature Communications.

[43]  P. Merkel,et al.  British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. , 2020, Rheumatology.

[44]  M. Isobe,et al.  Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study , 2020, Rheumatology.

[45]  Wenda Wang,et al.  An Observational Study of Sex Differences in Takayasu Arteritis in China: Implications for Worldwide Regional Differences. , 2019, Annals of vascular surgery.

[46]  Y. Shoenfeld,et al.  Mortality among Patients with Giant Cell Arteritis: A Large-scale Population-based Cohort Study , 2019, The Journal of Rheumatology.

[47]  H. Quick,et al.  PET/MRI Versus PET/CT for Whole-Body Staging: Results from a Single-Center Observational Study on 1,003 Sequential Examinations , 2019, The Journal of Nuclear Medicine.

[48]  P. Merkel,et al.  Outcome Measures in Large Vessel Vasculitis: Relationship Between Patient‐, Physician‐, Imaging‐, and Laboratory‐Based Assessments , 2019, Arthritis care & research.

[49]  M. Santiago,et al.  Association between Takayasu arteritis and latent or active Mycobacterium tuberculosis infection: a systematic review , 2019, Clinical Rheumatology.

[50]  P. Merkel,et al.  Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort , 2019, Arthritis & rheumatology.

[51]  Casey A. Rimland,et al.  Clinical symptoms and associated vascular imaging findings in Takayasu’s arteritis compared to giant cell arteritis , 2019, Annals of the rheumatic diseases.

[52]  P. Merkel,et al.  Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America. , 2019, Rheumatology.

[53]  F. Buttgereit,et al.  Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis , 2019, RMD Open.

[54]  F. Buttgereit,et al.  Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis , 2019, RMD Open.

[55]  M. Soussan,et al.  PET/MRI in large-vessel vasculitis: clinical value for diagnosis and assessment of disease activity , 2019, Scientific Reports.

[56]  M. González-Gay,et al.  Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. , 2019, Seminars in arthritis and rheumatism.

[57]  A. Sawalha,et al.  Takayasu arteritis risk locus in IL6 represses the anti-inflammatory gene GPNMB through chromatin looping and recruiting MEF2–HDAC complex , 2019, Annals of the rheumatic diseases.

[58]  C. Turesson,et al.  2018 Update of the EULAR recommendations for the management of large vessel vasculitis , 2019, Annals of the rheumatic diseases.

[59]  J. Stone,et al.  Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab , 2019, Arthritis & rheumatology.

[60]  L. Arnaud,et al.  Large-vessel vasculitis diagnosed between 50 and 60 years: Case-control study based on 183 cases and 183 controls aged over 60 years. , 2019, Autoimmunity reviews.

[61]  D. Bailey,et al.  Diagnostic Accuracy of Positron Emission Tomography/Computed Tomography of the Head, Neck, and Chest for Giant Cell Arteritis: A Prospective, Double‐Blind, Cross‐Sectional Study , 2019, Arthritis & rheumatology.

[62]  A. Tomelleri,et al.  Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis , 2019, Scandinavian journal of rheumatology.

[63]  R. Tehrani,et al.  Varicella Zoster Virus in Giant Cell Arteritis: A Review of Current Medical Literature , 2019, Neuro-ophthalmology.

[64]  C. Turesson,et al.  Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis , 2019, Scandinavian journal of rheumatology.

[65]  J. Stone,et al.  Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial , 2019, Arthritis Research & Therapy.

[66]  T. Nagao,et al.  Difference in immunohistochemical characteristics between Takayasu arteritis and giant cell arteritis: It may be better to distinguish them in the same age , 2019, Modern rheumatology.

[67]  N. Basu,et al.  Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study , 2019, BMC Nephrology.

[68]  D. Munoz,et al.  The incidence of giant cell arteritis in Ontario, Canada. , 2019, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[69]  E. Tombetti,et al.  Takayasu arteritis: advanced understanding is leading to new horizons , 2019, Rheumatology.

[70]  A. Diepstra,et al.  Massive B-Cell Infiltration and Organization Into Artery Tertiary Lymphoid Organs in the Aorta of Large Vessel Giant Cell Arteritis , 2019, Front. Immunol..

[71]  C. Crowson,et al.  Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study , 2019, The Journal of Rheumatology.

[72]  Colin Jones,et al.  Development of an evidence-based regimen of prednisolone to treat giant cell arteritis – the Norwich regimen , 2019, Rheumatology advances in practice.

[73]  A. Wakhlu,et al.  Recent advances in the management of Takayasu arteritis , 2019, International journal of rheumatic diseases.

[74]  Weili Zhang,et al.  Novel Biomarkers for the Precisive Diagnosis and Activity Classification of Takayasu Arteritis , 2019, Circulation. Genomic and precision medicine.

[75]  D. Hébert,et al.  Presentation and Disease Course of Childhood‐Onset Versus Adult‐Onset Takayasu Arteritis , 2018, Arthritis & rheumatology.

[76]  P. Giorgi Rossi,et al.  Survival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based study , 2018, Rheumatology.

[77]  D. Veale,et al.  Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial. , 2018, Seminars in arthritis and rheumatism.

[78]  Y. Okada,et al.  Genetic determinants and an epistasis of LILRA3 and HLA-B*52 in Takayasu arteritis , 2018, Proceedings of the National Academy of Sciences.

[79]  V. Gudnason,et al.  Cardiovascular risk factors and incident giant cell arteritis: a population-based cohort study , 2018, Scandinavian journal of rheumatology.

[80]  B. Ariff,et al.  Novel Angiographic Scores for evaluation of Large Vessel Vasculitis , 2018, Scientific Reports.

[81]  L. Tian,et al.  MMP (Matrix Metalloprotease)-9–Producing Monocytes Enable T Cells to Invade the Vessel Wall and Cause Vasculitis , 2018, Circulation research.

[82]  J. Ejlersen,et al.  Simple dichotomous assessment of cranial artery inflammation by conventional 18F-FDG PET/CT shows high accuracy for the diagnosis of giant cell arteritis: a case-control study , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[83]  M. Tomšič,et al.  The incidence of giant cell arteritis in Slovenia , 2018, Clinical Rheumatology.

[84]  P. Cacoub,et al.  Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature , 2018, Rheumatology.

[85]  A. Sreih,et al.  Vasculitis associated with immune checkpoint inhibitors—a systematic review , 2018, Clinical Rheumatology.

[86]  S. Reichenbach,et al.  Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis , 2018, Rheumatology.

[87]  G. Canaud,et al.  mTOR pathway is activated in endothelial cells from patients with Takayasu arteritis and is modulated by serum immunoglobulin G , 2018, Rheumatology.

[88]  T. Neogi,et al.  Mortality in Patients With Giant Cell Arteritis: A Cohort Study in UK Primary Care , 2018, Arthritis care & research.

[89]  H. Direskeneli,et al.  Discrepancies between vascular and systemic inflammation in large vessel vasculitis: an important problem revisited , 2018, Rheumatology.

[90]  R. Sehgal,et al.  Successful treatment with ustekinumab for corticosteroid- and immunosuppressant-resistant Takayasu’s arteritis , 2018, Scandinavian journal of rheumatology.

[91]  J. Grau,et al.  Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways , 2018, Front. Immunol..

[92]  L. Gormsen,et al.  Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[93]  P. Merkel,et al.  Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis , 2018, Annals of the rheumatic diseases.

[94]  G. Song,et al.  Endovascular Balloon Angioplasty versus Stenting in Patients With Takayasu Arteritis: A Meta‐Analysis , 2018 .

[95]  S. Ramiro,et al.  Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations , 2018, RMD Open.

[96]  A. Iagnocco,et al.  EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice , 2018, Annals of the rheumatic diseases.

[97]  P. Merkel,et al.  Impact of vasculitis on employment and income. , 2018, Clinical and experimental rheumatology.

[98]  C. Gjesdal,et al.  Incidence of giant cell arteritis in Western Norway 1972–2012: a retrospective cohort study , 2017, Arthritis Research & Therapy.

[99]  L. Barra,et al.  Imaging modalities for the diagnosis and disease activity assessment of Takayasu's arteritis: A systematic review and meta-analysis. , 2017, Autoimmunity reviews.

[100]  P. Merkel,et al.  Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016 , 2017, The Journal of Rheumatology.

[101]  P. Merkel,et al.  Assessment of Disease Activity in Large-vessel Vasculitis: Results of an International Delphi Exercise , 2017, The Journal of Rheumatology.

[102]  M. Isobe,et al.  Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study) , 2017, Annals of the rheumatic diseases.

[103]  L. Jayaseelan,et al.  Long-term outcome of 251 patients with Takayasu arteritis on combination immunosuppressant therapy: Single centre experience from a large tertiary care teaching hospital in Southern India. , 2017, Seminars in arthritis and rheumatism.

[104]  P. Cluzel,et al.  Long-Term Outcomes and Prognostic Factors of Complications in Takayasu Arteritis: A Multicenter Study of 318 Patients , 2017, Circulation.

[105]  M. Picchio,et al.  FDG Uptake by Prosthetic Arterial Grafts in Large Vessel Vasculitis Is Not Specific for Active Disease. , 2017, JACC. Cardiovascular imaging.

[106]  G. Berry,et al.  The immunoinhibitory PD‐1/PD‐L1 pathway in inflammatory blood vessel disease , 2017, Journal of leukocyte biology.

[107]  G. Berry,et al.  The microvascular niche instructs T cells in large vessel vasculitis via the VEGF-Jagged1-Notch pathway , 2017, Science Translational Medicine.

[108]  L. Cimino,et al.  Visual loss and other cranial ischaemic complications in giant cell arteritis , 2017, Nature Reviews Rheumatology.

[109]  Paul A. Renauer,et al.  The genetics of Takayasu arteritis. , 2017, Presse medicale.

[110]  Fatos Onen,et al.  Epidemiology of Takayasu arteritis. , 2017, Presse medicale.

[111]  M. Alba,et al.  Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis , 2017, Annals of the rheumatic diseases.

[112]  J. Stone,et al.  Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis. , 2017, Seminars in arthritis and rheumatism.

[113]  Ø. Molberg,et al.  TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study , 2017, Arthritis Research & Therapy.

[114]  H. Ahn,et al.  Incidence, prevalence, mortality and causes of death in Takayasu Arteritis in Korea - A nationwide, population-based study. , 2017, International journal of cardiology.

[115]  L. Barra,et al.  Variations in the clinical practice of physicians managing Takayasu arteritis: a nationwide survey , 2017, Open access rheumatology : research and reviews.

[116]  V. Fuster,et al.  Clinical Utility of Combined FDG-PET/MR to Assess Myocardial Disease. , 2017, JACC. Cardiovascular imaging.

[117]  J. Krischer,et al.  A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Takayasu Arteritis , 2017, Arthritis & rheumatology.

[118]  J. Krischer,et al.  A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis , 2017, Arthritis & rheumatology.

[119]  J. Nossent,et al.  Frequency, presentation, and outcome of Takayasu arteritis in Western Australia , 2017, Modern rheumatology.

[120]  P. Merkel,et al.  Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy , 2017, Scientific Reports.

[121]  G. Hunder,et al.  Clinical and Pathological Evolution of Giant Cell Arteritis: A Prospective Study of Follow-Up Temporal Artery Biopsies in 40 Treated Patients , 2017, Modern Pathology.

[122]  R. Luqmani,et al.  Development of a score for assessment of radiologic damage in large-vessel vasculitis (Combined Arteritis Damage Score, CARDS). , 2017, Clinical and experimental rheumatology.

[123]  C. Salvarani,et al.  Incidence, Prevalence, and Survival of Biopsy‐Proven Giant Cell Arteritis in Northern Italy During a 26‐Year Period , 2017, Arthritis care & research.

[124]  Ø. Molberg,et al.  Prevalence, Incidence, and Disease Characteristics of Takayasu Arteritis by Ethnic Background: Data From a Large, Population‐Based Cohort Resident in Southern Norway , 2017, Arthritis care & research.

[125]  R. Black,et al.  Risk of mortality in patients with giant cell arteritis: A systematic review and meta-analysis. , 2017, Seminars in arthritis and rheumatism.

[126]  G. Berry,et al.  Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis , 2017, Proceedings of the National Academy of Sciences.

[127]  C. Wijmenga,et al.  A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. , 2017, American journal of human genetics.

[128]  J. Stone,et al.  An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy , 2016, Annals of the rheumatic diseases.

[129]  M. Bradburn,et al.  The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. , 2016, Health technology assessment.

[130]  B. Bonnotte,et al.  Involvement and prognosis value of CD8(+) T cells in giant cell arteritis. , 2016, Journal of autoimmunity.

[131]  G. Nesher,et al.  The Incidence of Primary Systemic Vasculitis in Jerusalem: A 20-year Hospital-based Retrospective Study , 2016, The Journal of Rheumatology.

[132]  S. Reichenbach,et al.  Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial , 2016, The Lancet.

[133]  Ji-hang Ju,et al.  NADPH oxidase deficiency underlies dysfunction of aged CD8+ Tregs. , 2016, The Journal of clinical investigation.

[134]  B. Luke,et al.  Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling , 2016, Science Signaling.

[135]  H. Direskeneli,et al.  The epidemiology of Takayasu arteritis: a hospital-based study from northwestern part of Turkey , 2016, Rheumatology International.

[136]  W. Dixon,et al.  Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force , 2016, Annals of the rheumatic diseases.

[137]  E. Matteson,et al.  Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. , 2016, Rheumatology.

[138]  A. Mazzone,et al.  The prognostic value of baseline 18F-FDG PET/CT in steroid-naïve large-vessel vasculitis: introduction of volume-based parameters , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[139]  Harry Hemingway,et al.  Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases , 2016, Heart.

[140]  J. Henes,et al.  MRI parametric monitoring of biological therapies in primary large vessel vasculitides: a pilot study. , 2016, The British journal of radiology.

[141]  C. Terao,et al.  Ustekinumab as a therapeutic option for Takayasu arteritis: from genetic findings to clinical application , 2016, Scandinavian journal of rheumatology.

[142]  A. Enjuanes,et al.  Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis , 2015, Annals of the rheumatic diseases.

[143]  E. Messas,et al.  Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients. , 2015, Circulation.

[144]  T. Miyata,et al.  Current Clinical Features of New Patients With Takayasu Arteritis Observed From Cross-Country Research in Japan: Age and Sex Specificity , 2015, Circulation.

[145]  A. Rizzo,et al.  Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis. , 2015, Rheumatology.

[146]  P. Merkel,et al.  Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study , 2015, The Journal of Rheumatology.

[147]  Dinesh Kumar,et al.  NMR-Based Serum Metabolomics Discriminates Takayasu Arteritis from Healthy Individuals: A Proof-of-Principle Study. , 2015, Journal of proteome research.

[148]  C. Weber,et al.  Artery Tertiary Lymphoid Organs Control Aorta Immunity and Protect against Atherosclerosis via Vascular Smooth Muscle Cell Lymphotoxin β Receptors , 2015, Immunity.

[149]  B. Nan,et al.  DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis , 2015, Annals of the rheumatic diseases.

[150]  R. Slart,et al.  OP0236 Different Scoring Methods of FDG PET/CT in Giant Cell Arteritis: Need for Standardization , 2015 .

[151]  E. Matteson,et al.  The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950–2009 , 2015, Scandinavian journal of rheumatology.

[152]  P. Cluzel,et al.  Th1 and Th17 Cytokines Drive Inflammation in Takayasu Arteritis , 2015, Arthritis & rheumatology.

[153]  P. Merkel,et al.  Identification of Susceptibility Loci in IL6, RPS9/LILRB3, and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genome‐Wide Association Study , 2015 .

[154]  T. Mandl,et al.  Takayasu Arteritis in Southern Sweden , 2015, The Journal of Rheumatology.

[155]  E. Matteson,et al.  Large-vessel giant cell arteritis: a cohort study. , 2015, Rheumatology.

[156]  P. Calleja,et al.  Intracranial Internal Carotid Artery Angioplasthy and Stenting in Giant Cell Arteritis , 2015, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[157]  J. Hernández-Rodríguez,et al.  Epidemiological study of primary systemic vasculitides among adults in southern Spain and review of the main epidemiological studies. , 2015, Clinical and experimental rheumatology.

[158]  Marcelo Sánchez,et al.  Effect of Glucocorticoid Treatment on Computed Tomography Angiography Detected Large-Vessel Inflammation in Giant-Cell Arteritis. A Prospective, Longitudinal Study , 2015, Medicine.

[159]  A. Chaudhry,et al.  Clinical Features and Radiological Findings in Large Vessel Vasculitis: Are Takayasu Arteritis and Giant Cell Arteritis 2 Different Diseases or a Single Entity? , 2015, The Journal of Rheumatology.

[160]  Haiying Wu,et al.  Clinical Manifestations and Longterm Outcome for Patients with Takayasu Arteritis in China , 2014, The Journal of Rheumatology.

[161]  C. Pusey,et al.  Issues in trial design for ANCA-associated and large-vessel vasculitis , 2014, Nature Reviews Rheumatology.

[162]  P. Kluin,et al.  Disturbed B Cell Homeostasis in Newly Diagnosed Giant Cell Arteritis and Polymyalgia Rheumatica , 2014, Arthritis & rheumatology.

[163]  M. Alba,et al.  Relapses in Patients With Giant Cell Arteritis , 2014, Medicine.

[164]  M. Essler,et al.  Imaging large vessel vasculitis with fully integrated PET/MRI: a pilot study , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[165]  A. Kinderlerer,et al.  Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-α and IL-6 receptor targeted therapies in refractory Takayasu arteritis. , 2014, Clinical and experimental rheumatology.

[166]  Yoav Ben-Shlomo,et al.  Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. , 2014, Journal of the American College of Cardiology.

[167]  M. Perretti,et al.  Investigational Analysis Reveals a Potential Role for Neutrophils in Giant-Cell Arteritis Disease Progression , 2014, Circulation research.

[168]  R. Black,et al.  Epidemiology of biopsy‐proven giant cell arteritis in South Australia , 2014, Internal medicine journal.

[169]  J. Wolfe,et al.  Optimizing the outcome of vascular intervention for Takayasu arteritis , 2014, The British journal of surgery.

[170]  C. Weyand,et al.  Immune mechanisms in medium and large-vessel vasculitis , 2013, Nature Reviews Rheumatology.

[171]  Sung W. Shin,et al.  Long term results of endovascular treatment in renal arterial stenosis from Takayasu arteritis: angioplasty versus stent placement. , 2013, European journal of radiology.

[172]  Rajiva Gupta,et al.  Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). , 2013, Rheumatology.

[173]  A. Diamantopoulos,et al.  Leflunomide as a Corticosteroid-Sparing Agent in Giant Cell Arteritis and Polymyalgia Rheumatica: A Case Series , 2013, BioMed research international.

[174]  L. Kanz,et al.  Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis. , 2013, Rheumatology.

[175]  N. Braun,et al.  Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis , 2013, Annals of the rheumatic diseases.

[176]  T. Kawaguchi,et al.  Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. , 2013, American journal of human genetics.

[177]  P. Merkel,et al.  Identification of multiple genetic susceptibility loci in Takayasu arteritis. , 2013, American journal of human genetics.

[178]  C. Pagnoux,et al.  Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. , 2013, Seminars in arthritis and rheumatism.

[179]  L. Cooper,et al.  Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients. , 2013, Mayo Clinic proceedings.

[180]  G. Baron,et al.  Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial , 2013, Annals of the rheumatic diseases.

[181]  S. Gabriel,et al.  Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis , 2012, Annals of the rheumatic diseases.

[182]  S. Unizony,et al.  Tocilizumab for the treatment of large‐vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica , 2012, Arthritis care & research.

[183]  Mahboob Rahman,et al.  Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis , 2012, Annals of the rheumatic diseases.

[184]  D. Klatzmann,et al.  Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. , 2012, Arthritis and rheumatism.

[185]  A. Mantovani,et al.  Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia. , 2012, Arthritis and rheumatism.

[186]  P. Cluzel,et al.  Retrospective Analysis of Surgery Versus Endovascular Intervention in Takayasu Arteritis: A Multicenter Experience , 2012, Circulation.

[187]  P. Merkel,et al.  Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis , 2012, Annals of the rheumatic diseases.

[188]  C. Doglioni,et al.  Pentraxin-3 as a Marker of Disease Activity in Takayasu Arteritis , 2011, Annals of Internal Medicine.

[189]  M. Alba,et al.  Central Nervous System Vasculitis: Still More Questions than Answers , 2011, Current neuropharmacology.

[190]  Y. J. Liao,et al.  Giant cell arteritis: immune and vascular aging as disease risk factors , 2011, Arthritis research & therapy.

[191]  A. Molteno,et al.  The epidemiology of giant cell arteritis in Otago, New Zealand: a 9-year analysis. , 2011, The New Zealand medical journal.

[192]  M. Desai,et al.  Blocking the NOTCH Pathway Inhibits Vascular Inflammation in Large-Vessel Vasculitis , 2011, Circulation.

[193]  I. Marie,et al.  Long-Term Follow-Up of Upper and Lower Extremity Vasculitis Related to Giant Cell Arteritis: A Series of 36 Patients , 2011, Medicine.

[194]  Oliver Gaemperli,et al.  Detection and Quantification of Large-Vessel Inflammation with 11C-(R)-PK11195 PET/CT , 2011, The Journal of Nuclear Medicine.

[195]  S. Gabriel,et al.  Epidemiology of large-vessel vasculidities. , 2010, Best practice & research. Clinical rheumatology.

[196]  O. Karadag,et al.  Assessment of disease activity and progression in Takayasu's arteritis with Disease Extent Index-Takayasu. , 2010, Rheumatology.

[197]  A. Davies,et al.  Imaging of vascular inflammation with [11C]-PK11195 and positron emission tomography/computed tomography angiography. , 2010, Journal of the American College of Cardiology.

[198]  M. Cid,et al.  Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor α and interleukin‐6) in the long‐term followup of patients with giant cell arteritis , 2010, Arthritis care & research.

[199]  H. Mariz,et al.  Antiplatelet therapy for the prevention of arterial ischemic events in takayasu arteritis. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[200]  R. Olshen,et al.  Th17 and Th1 T-Cell Responses in Giant Cell Arteritis , 2010, Circulation.

[201]  P. Cluzel,et al.  Takayasu Arteritis in France: A Single-Center Retrospective Study of 82 Cases Comparing White, North African, and Black Patients , 2010, Medicine.

[202]  S. Gabriel,et al.  Increase in age at onset of giant cell arteritis: a population-based study , 2009, Annals of the rheumatic diseases.

[203]  Javier Martín,et al.  Epidemiology of giant cell arteritis and polymyalgia rheumatica. , 2009, Arthritis and rheumatism.

[204]  D. Scott,et al.  The epidemiology of Takayasu arteritis in the UK. , 2009, Rheumatology.

[205]  Javier Martín,et al.  Association Between Toll-like Receptor 4 Gene Polymorphism and Biopsy-proven Giant Cell Arteritis , 2009, The Journal of Rheumatology.

[206]  Kogstad Oa.  Polymyalgia rheumatica and its relation to arteritis temporalis. , 2009 .

[207]  T. Mader,et al.  Giant cell arteritis in Alaska Natives. , 2009, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[208]  Olga Pryshchep,et al.  Vessel-Specific Toll-Like Receptor Profiles in Human Medium and Large Arteries , 2008, Circulation.

[209]  Tak-Lam Wong,et al.  Temporal arteritis in Hong Kong , 2008 .

[210]  D. Solmaz,et al.  Quality of life in patients with Takayasu's arteritis is impaired and comparable with rheumatoid arthritis and ankylosing spondylitis patients , 2008, Clinical Rheumatology.

[211]  M. Soto,et al.  Takayasu arteritis: clinical features in 110 Mexican Mestizo patients and cardiovascular impact on survival and prognosis. , 2008, Clinical and experimental rheumatology.

[212]  J. Nolla,et al.  Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. , 2008, Clinical and experimental rheumatology.

[213]  E. Mola,et al.  A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects , 2007, Annals of the rheumatic diseases.

[214]  P. Merkel,et al.  Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. , 2007, Arthritis and rheumatism.

[215]  M. Cid,et al.  Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis , 2007, Annals of the rheumatic diseases.

[216]  J. Grau,et al.  Gelatinase expression and proteolytic activity in giant-cell arteritis , 2007, Annals of the rheumatic diseases.

[217]  Mahboob Rahman,et al.  Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis , 2007, Annals of Internal Medicine.

[218]  Javier Martín,et al.  Giant Cell Arteritis in Northwestern Spain: A 25-Year Epidemiologic Study , 2007, Medicine.

[219]  K. Maksimowicz-McKinnon,et al.  Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. , 2007, Arthritis and rheumatism.

[220]  R. Kardon,et al.  Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. , 2006, Ophthalmology.

[221]  F. Dockery,et al.  Takayasu's arteritis: a cause of prolonged arterial stiffness. , 2006, Rheumatology.

[222]  L. Mortelmans,et al.  Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. , 2006, Arthritis and rheumatism.

[223]  N. Seyahi,et al.  Atherosclerosis in Takayasu arteritis , 2006, Annals of the rheumatic diseases.

[224]  L. Smeeth,et al.  Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001 , 2006, Annals of the rheumatic diseases.

[225]  K. Yamada,et al.  Dual function of focal adhesion kinase in regulating integrin‐induced MMP‐2 and MMP‐9 release by human T lymphoid cells , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[226]  Javier Martín,et al.  A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. , 2005, The Journal of rheumatology.

[227]  M. Mamdani,et al.  Giant cell arteritis and cardiovascular disease in older adults , 2005, Heart.

[228]  M. Singh,et al.  Cellular and humoral immune responses to mycobacterial heat shock protein‐65 and its human homologue in Takayasu's arteritis , 2004, Clinical and experimental immunology.

[229]  S. Gabriel,et al.  Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. , 2004, Arthritis and rheumatism.

[230]  S. Yamashita,et al.  Matrix metalloproteinases as novel disease markers in Takayasu arteritis. , 2004, Circulation.

[231]  T. Tedder,et al.  Activation of Arterial Wall Dendritic Cells and Breakdown of Self-tolerance in Giant Cell Arteritis , 2004, The Journal of experimental medicine.

[232]  D. Colomer,et al.  Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. , 2003, Rheumatology.

[233]  H. Rubin,et al.  Domains of health-related quality of life important to patients with giant cell arteritis. , 2003, Arthritis and rheumatism.

[234]  S. Gabriel,et al.  Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. , 2003, Arthritis and rheumatism.

[235]  K. Yasuda,et al.  Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. , 2003, Arthritis and rheumatism.

[236]  C. Nordborg,et al.  Giant cell arteritis: epidemiological clues to its pathogenesis and an update on its treatment. , 2003, Rheumatology.

[237]  K. Kalunian,et al.  A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. , 2002, Arthritis and rheumatism.

[238]  E. Gromnica-ihle,et al.  Involvement of peripheral arteries in giant cell arteritis: a color Doppler sonography study. , 2002, Clinical and experimental rheumatology.

[239]  T. Wilsgaard,et al.  Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. , 2001, Rheumatology.

[240]  M. Peterson,et al.  A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). , 2001, Clinical and experimental rheumatology.

[241]  J. Jover,et al.  Combined Treatment of Giant-Cell Arteritis with Methotrexate and Prednisone , 2001, Annals of Internal Medicine.

[242]  W. Thomson,et al.  Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms. , 2000, Arthritis and rheumatism.

[243]  J. Evans,et al.  Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. , 2000, Arthritis and rheumatism.

[244]  A. Ranzi,et al.  Intercellular adhesion molecule 1 gene polymorphisms in polymyalgia rheumatica/giant cell arteritis: association with disease risk and severity. , 2000, The Journal of rheumatology.

[245]  I. Yamada,et al.  Takayasu arteritis: Diagnosis with breath‐hold contrast‐enhanced three‐dimensional MR angiography , 2000, Journal of magnetic resonance imaging : JMRI.

[246]  C. Yutani,et al.  Immunophenotypic Analysis of the Aortic Wall in Takayasu's Arteritis: Involvement of Lymphocytes, Dendritic Cells and Granulocytes in Immuno-Inflammatory Reactions , 2000, Cardiovascular surgery.

[247]  C. Weyand,et al.  Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. , 1999, The American journal of pathology.

[248]  J. Gran,et al.  The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987-94. , 1997, The Journal of rheumatology.

[249]  A. Brack,et al.  Giant Cell Vasculitis Is a T Cell-Dependent Disease , 1997, Molecular medicine.

[250]  J. Anim,et al.  Takayasu's arteritis in Kuwait. , 1995, The Journal of tropical medicine and hygiene.

[251]  R. Moots,et al.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. , 1994, QJM : monthly journal of the Association of Physicians.

[252]  G. Hunder,et al.  Tissue Cytokine Patterns in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis , 1994, Annals of Internal Medicine.

[253]  C. Salvarani,et al.  Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. , 1991, Arthritis and rheumatism.

[254]  P. Boesen,et al.  Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county. A prospective investigation, 1982-1985. , 1987, Arthritis and rheumatism.

[255]  G. Hunder,et al.  Takayasu Arteritis: A STUDY OF 32 NORTH AMERICAN PATIENTS , 1985 .

[256]  C. Smith,et al.  The epidemiology of giant cell arteritis. Report of a ten-year study in Shelby County, Tennessee. , 1983, Arthritis and rheumatism.

[257]  J. Benbassat,et al.  Epidemiology of temporal arteritis in Israel. , 1982, Israel journal of medical sciences.

[258]  B. Hamrin.  Polymyalgia arteritica. , 1977, Acta medica Scandinavica. Supplementum.

[259]  S. Hellsten,et al.  "Polymyalgia arteritica". Further clinical and histopathological studies with a report of six autopsy cases. , 1968, Annals of the rheumatic diseases.

[260]  T. Nasu.  Pathology of Pulseless Disease , 1963, Angiology.

[261]  J. Gilmour.  Giant-cell chronic arteritis , 1941 .

[262]  George E. Brown,et al.  ARTERITIS OF THE TEMPORAL VESSELS: A PREVIOUSLY UNDESCRIBED FORM , 1934 .

[263]  M. Grainge,et al.  Systematic review and meta analysis A systematic review and meta-analysis of the incidence rate of Takayasu arteritis , 2021 .

[264]  P. Cluzel,et al.  Overall survival and mortality risk factors in Takayasu's arteritis: A multicenter study of 318 patients. , 2019, Journal of autoimmunity.

[265]  A. Rizzo,et al.  Increased expression of interleukin-22 in patients with giant cell arteritis , 2018, Rheumatology.

[266]  D. Bluemke,et al.  F-Fluorodeoxyglucose–Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis , 2018 .

[267]  V. Fuster,et al.  Nuclear cardiology in the literature: A selection of recent, original research papers , 2018, Journal of Nuclear Cardiology.

[268]  Hyon K. Choi,et al.  Increased risk of cardiovascular disease in giant cell arteritis: a general population-based study. , 2016, Rheumatology.

[269]  G. Haugeberg,et al.  The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? , 2016, Rheumatology.

[270]  N. Arden,et al.  The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. , 2015, Annals of the rheumatic diseases.

[271]  A. Davies,et al.  Imaging of Vascular Inflammation with [C]-PK11195 and PET/CT Angiography , 2015 .

[272]  Javier Martín,et al.  Genetic component of giant cell arteritis. , 2014, Rheumatology.

[273]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[274]  L. Dreyer,et al.  A population-based study of Takayasu´s arteritis in eastern Denmark. , 2011, Clinical and experimental rheumatology.

[275]  A. Sidawy,et al.  Quality of life of patients with Takayasu's arteritis. , 2008, Journal of vascular surgery.

[276]  金子 文成,et al.  長時間歩行時の下肢筋の活動状態:[ 18 F]fluorodeoxyglucoseを用いたPositron Emission Tomographyによる検討 , 2008 .

[277]  S. Hayat.  Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis: A Randomized Trial , 2008 .

[278]  Andreas Krause,et al.  Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. , 2008, Rheumatology.

[279]  M. Sonnenblick,et al.  The incidence of giant cell arteritis in Jerusalem over a 25-year period: annual and seasonal fluctuations. , 2007, Clinical and experimental rheumatology.

[280]  K. Koide.  Takayasu arteritis in Japan , 2005, Heart and Vessels.

[281]  Guy Hoffman,et al.  Takayasu Arteritis , 1994, Annals of Internal Medicine.

[282]  P. Boesen,et al.  Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county. A prospective investigation, 1982-1985. , 1987, Arthritis and rheumatism.

[283]  O. Kogstad.  Polymyalgia rheumatica and its relation to arteritis temporalis. , 1965, Acta medica Scandinavica.